GCM
CTKB icon

Ghisallo Capital Management’s Cytek Biosciences CTKB Stock Holding History

Ghisallo Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.07M – 473
2021
Q3 		$1.07M Buy
+50,000
New +$1.18M 0.04% 368

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ghisallo Capital Management's CTKB Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Cytek Biosciences (CTKB) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.07M sold.

Ghisallo Capital Management first reported a position in CTKB in Q3 2021 and held it in 1 quarter. The position peaked at $1.07M in Q3 2021. 52 funds tracked by Wall St. Rank hold CTKB as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Cytek Biosciences position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 50,000 Cytek Biosciences shares in Q4 2021, an estimated $1.07M.
  • Ghisallo Capital Management first reported a position in Cytek Biosciences in Q3 2021 and held it in 1 quarter.
  • Ghisallo Capital Management's Cytek Biosciences position peaked at $1.07M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.